April 12, 2017
Roche to launch new biomarker for prostate cancer diagnosis
Roche has announced the global launch of the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody2 for prostate cancer diagnosis.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
April 12, 2017
FDA OKs Neurocrine Biosciences’s neurological disorder drug
The U.S. Food and Drug Administration has approved Neurocrine Biosciences’s Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia.
April 11, 2017
Nicox announces PDUFA date for Zerviate NDA
U.S. Food and Drug Administration (FDA) has set a PDUFA date of September 8, 2017 for its decision on the New Drug Application (NDA) for Nicox’s Zerviate (cetirizine ophthalmic solution) 0.24%.
April 7, 2017
FDA OK’s Gilead Sciences’s hepatitis C drug for pediatric patients
U.S. Food and Drug Administration (FDA) has approved supplemental indications for Gilead Sciences’s Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg) tablets and Sovaldi (sofosbuvir 400 mg) tablets for the treatment of chronic hepatitis C virus (HCV) infection in adolescents without cirrhosis or with compensated cirrhosis, 12 years of age and older, or weighing at least 35kg.
April 7, 2017
Medivir aims $900 million US market with a certain skin cancer treatment
There are few drugs available for the treatment of the disease, and those currently available have generally poor tolerability. As a result, CTCL patients and their physicians require safe and effective new treatment options, said Dr Richard Bethell, Medivir’s Chief Scientific Officer.
April 6, 2017
Novartis in-licenses dry eye therapeutic ECF843 worldwide
Novartis said Thursday it has exercised an option to in-license ECF843 for ophthalmic indications worldwide excepot of Europe, without revealing financial and other terms of this transaction.
April 6, 2017
Zavante Therapeutics’ Zolyd met goal in a study for treating urinary tract infections
Zavante Therapeutics’ investigational product candidate, Zolyd (fosfomycin for injection, also known as ZTI-01), met the primary endpoint of statistical non-inferiority to piperacillin/tazobactam.
April 6, 2017
Barlow starts as CEO at e-Therapeutics
e-Therapeutics, the drug discovery company, announced Thursday that Dr. Raymond Barlow has assumed his position as Chief Executive Officer.
April 6, 2017
PureTech’s Akili pilot study shows improved cognitive control in children with sensory processing dysfunction and attentional deficits
PureTech Health’s subsidiary Akili announced results from a project EVO pilot study demonstrating improved cognitive control in children with sensory processing dysfunction and attentional deficits.
April 6, 2017
NHS England’s third clinical fellowship scheme
NHS England is now inviting for the 2017 Clinical Fellowship Scheme for practising pharmacists.